Close

Singapore Seeking Pharmaceutical Tariff Concessions from US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

The deputy prime minister and trade minister of Singapore, Gan Kim Yong, has announced his plans to visit Washington this July in order to negotiate certain pharmaceutical tariff concessions on exports, thereby looking forward to shielding one of the most vital industries of the country from the widening US-led trade conflict. Although Singapore has not yet received a direct tariff warning letter from President Donald Trump’s administration as yet, its exports are still subject to a 10% baseline tariff, which is imposed under the reciprocal trade policy, which was initiated in April 2025. In spite of a free trade agreement with the US, since 2004, the higher-value pharmaceutical as well as electronics shipments from Singapore remain exposed to new levies, thereby raising concerns when it comes to the integrity of established trade practices along with certain economic effects on export-dependent sectors.

Tariff escalation happens to pose a risk to semiconductor as well as pharma trade

The recent announcement by the Trump administration of a 50% copper tariff, as well as the planned extension of tariffs on semiconductors along with pharmaceuticals, has raised alarms in Singapore, which happens to be a nation where advanced manufacturing along with biopharmaceuticals comprise almost 40% of overall exports to the United States, as per the Monetary Authority of Singapore. The vulnerability of the island happens to lie in the sector-specific nature of the present trade war, since broad industrial categories go on to fall under the retaliatory scope of Washington.

The minister went on to note that while the discussion when it comes to semiconductors has not started yet, they happen to remain a priority once the pharmaceutical issues are settled. The global semiconductor supply chain integration of Singapore, both as a producer as well as a logistics hub, makes it a potential collateral victim when it comes to the broader technology decoupling that has happened between the US as well as Asia.

As the front-loading has faded, the domestic outlook is cautiously revised

Gan also went on to flag slowing economic momentum within the second half of 2025, with earlier growth sustained primarily because of front-loaded exports, which were ahead of anticipated tariff hikes. The Ministry of Trade and Industry has already lowered the GDP growth projections in April 2025 to hover between 0% and 2% from the erstwhile 1% to 3% outlook. The revision goes on to reflect the repercussions of both the direct impact of tariffs along with the anticipated decline in external demand since global supply chains have reshuffled.

As Singapore is deeply embedded within both Western as well as Asian trade networks, the convergence of US protectionism along with Chinese countermeasures happens to create a very specific, delicate, diplomatic as well as economic balancing act. The latest warning by China of retaliation against countries that are supporting the US supply chain alignment highlights that the geopolitical tightrope has to be navigated by Singapore.

Trade diplomacy, which is under pressure

The urgency of the upcoming negotiations by Singapore happens to be compounded by the letters from Trump to 22 countries recently, which include very close allies like South Korea and Japan, thereby outlining tariffs of 20 to 50% that are going to set to take effect from August 1. While Singapore has not received any such letter yet, the uncertainty that is surrounding the sector-specific enforcement happens to mean that even countries that are not directly named may face the second-order effects by way of decreased global trade flows and even redirected capital.

Gan has gone ahead and adopted a carefully structured approach to trade relations and prioritize the stabilization of the pharmaceutical sector before going ahead and addressing the complex semiconductor industry. This kind of phased strategy is designed in order to minimize economic exposure and at the same time allow with a measured progress in trade negotiations. By way of focusing first on pharmaceuticals, which is a critical sector with direct implications for public health as well as domestic stability, the government looks forward to establishing a foundation of dependability before going ahead and tackling the technology-intensive semiconductor market, which happens to involve higher stakes in terms of global competition along with supply chain dependencies.

This sort of cautious methodology happens to reflect a deliberate effort in order to balance risk management along with strategic advancement. By way of limiting initial exposure to one sector at a time, policymakers can better evaluate outcomes, adjust their tactics, and also maintain certain open channels. For diplomatic dialogue. However, this kind of approach is not without challenges. The consistent threat of retaliatory escalation from the Trump administration, especially in response to the tariffs, happens to create an environment of uncertainty when it comes to trade-dependent economies such as Singapore. Such retaliatory measures could even force nations into a defensive stance, thereby compelling them to react rather than pursue proactive economic policies.

The wide implication of all this is that the global trade dynamics remain volatile with smaller economies, specifically the ones that are vulnerable to shifts in US trade policy. While the phased strategy used by Gan offers a buffer against sudden disruptions, this specter of unpredictable tariff war keeps many nations in a very reactive posture by complicating long-term planning as well as investment. This highlights the delicate balance between protecting domestic industries and also engaging in competitive global trade.

It is well to be noted that as Washington continues with its aggressive trade recalibration, the visit by Singapore in order to negotiate pharmaceutical tariff concessions happens to be a critical effort in order to preserve one of its economic pillars. While the outcome still remains uncertain, the wider risk happens to lie in the trust erosion within existing trade agreements and also the ripple impact on global growth. With these kinds of sectorial tariffs expanding and geopolitical alignment also shifting, the calibrated diplomacy by Singapore is indeed essential in order to navigate the next phase of turbulence within the trade.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »